Nutrients, Vol. 18, Pages 921: Curcumin-Loaded Lactoferrin/Pectin Core–Shell Structured Microgel Nanoparticles: Dual Regulatory Effects in Alleviating Inflammatory Bowel Disease
Nutrients doi: 10.3390/nu18060921
Authors:
Ming-Yu Jin
Sai-Yin Yu
Er-Feng Wang
Henan Zhang
Jing-Yi Xu
Chen Wang
Long-Qing Li
Jing-Kun Yan
Background: Curcumin (Cur) has therapeutic potential for inflammatory bowel disease (IBD) but is limited by its poor bioavailability. Methods: This study demonstrated that Cur-loaded core–shell structured microgel nanoparticles (LF/CP-Cur MN), fabricated through electrostatic complexation between lactoferrin and citrus pectin, followed by Ca2+ consolidation, overcome this limitation. Results: These nanoparticles effectively reduced the bitterness and astringency of curcumin while prolonging its release time. In an IBD mouse model, LF/CP-Cur MN treatment mitigated symptoms and inflammation of IBD, and restored intestinal barrier integrity. Crucially, compared with free Cur, the LF/CP-Cur MN enhanced colon-targeted accumulation of Cur and favorably modulated the gut microbiota by increasing beneficial genera like Lactobacillus and Dubosiella, while suppressing harmful genera like Enterobacter, thereby promoting levels of acetate, propionate, and butyrate. Conclusions: These findings highlight the potential of the LF/CP-Cur MN to improve Cur bioaccessibility and exert dual functional roles in modulating gut microbiota and alleviating inflammation, thus offering a promising dietary strategy for the management of IBD.
Background: Curcumin (Cur) has therapeutic potential for inflammatory bowel disease (IBD) but is limited by its poor bioavailability. Methods: This study demonstrated that Cur-loaded core–shell structured microgel nanoparticles (LF/CP-Cur MN), fabricated through electrostatic complexation between lactoferrin and citrus pectin, followed by Ca2+ consolidation, overcome this limitation. Results: These nanoparticles effectively reduced the bitterness and astringency of curcumin while prolonging its release time. In an IBD mouse model, LF/CP-Cur MN treatment mitigated symptoms and inflammation of IBD, and restored intestinal barrier integrity. Crucially, compared with free Cur, the LF/CP-Cur MN enhanced colon-targeted accumulation of Cur and favorably modulated the gut microbiota by increasing beneficial genera like Lactobacillus and Dubosiella, while suppressing harmful genera like Enterobacter, thereby promoting levels of acetate, propionate, and butyrate. Conclusions: These findings highlight the potential of the LF/CP-Cur MN to improve Cur bioaccessibility and exert dual functional roles in modulating gut microbiota and alleviating inflammation, thus offering a promising dietary strategy for the management of IBD. Read More